Classifying ultra-high risk smoldering myeloma

Leukemia

Volumn 29, Issue 3, 2015, Pages 751-753

  Waxman, A J ^a   Mick, R ^b   Garfall, A L ^a   Cohen, A ^a   Vogl, D T ^a   Stadtmauer, E A ^a   Weiss, B M ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; IL6 PROTEIN, HUMAN; IMMUNOGLOBULIN LIGHT CHAIN; INTERLEUKIN 6; SERUM ALBUMIN; TUMOR MARKER;

ADULT; ALBUMIN BLOOD LEVEL; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; FEMALE; HIGH RISK PATIENT; HUMAN; ICD-9; INTERMEDIATE RISK PATIENT; LETTER; LIGHT CHAIN; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PLASMACYTOMA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SMOLDERING MULTIPLE MYELOMA; AGED; BLOOD; CLASSIFICATION; DISEASE COURSE; FOLLOW UP; METABOLISM; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; NEOPLASMS, PLASMA CELL; PATHOLOGY; PATIENT SELECTION; RISK FACTOR; STATISTICAL MODEL;

AGED; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; INTERLEUKIN-6; MALE; MIDDLE AGED; MODELS, STATISTICAL; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; NEOPLASMS, PLASMA CELL; PATIENT SELECTION; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TUMOR MARKERS, BIOLOGICAL;

EID: 84924626880     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.313     Document Type: Letter

References (16)

1. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 2009; 113: 5418-5422.
2. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412-5417.
3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
4. Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-2592.
5. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008; 111: 785-789.
6. Mateos M-V, Hernández M-T, Giraldo P, la Rubia de J, de Arriba F, López Corral L et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med 2013; 369: 438-447.
7. Dispenzieri A, Stewart AK, Chanan-Khan A, Rajkumar SV, Kyle RA, Fonseca R et al. Smoldering multiple myeloma requiring treatment: time for a new definition? Blood 2013; 122: 4172-4181.
8. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2012; 27: 941-946.
9. Neben K, Jauch A, Hielscher T, Hillengass J, Lehners N, Seckinger A et al. Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 2013; 31: 4325-4332.
10. Rajkumar SV, Gupta V, Fonseca R, Dispenzieri A, Gonsalves WI, Larson D et al. Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma. Leukemia 2013; 27: 1738-1744.
11. Dhodapkar MV, Sexton R, Waheed S, Usmani S, Papanikolaou X, Nair B et al. Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120). Blood 2014; 123: 78-85.
12. Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M et al. Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study. Leuk Lymphoma 2013; 54: 2215-2218.
13. Rajkumar SV, Larson D, Kyle RA. Diagnosis of smoldering multiple myeloma. N Engl J Med 2011; 365 : 474-475.
14. Greipp PR. International Staging System for Multiple Myeloma. J Clin Oncol 2005; 23: 3412-3420.
15. Bologa RM, Levine DM, Parker TS, Cheigh JS, Serur D, Stenzel KH et al. Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am J Kidney Dis 1998; 32: 107-114.
16. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E et al. Extensive bone marrow infiltration and abnormal freelight chain ratio identifies patients with asymptomatic myelomaat high risk for progression to symptomatic disease. Leukemia 2012; 27: 947-953.